Evidence map›Paper›PMID 40756600›Full record

ReviewFrontiers in cardiovascular medicine2025

Research status of triglyceride glucose-body mass index (TyG-BMI index).

Ke Song, Yuwan Xu, Shuairan Wu, Xiaojie Zhang, Yi Wang, Sancong Pan

Registry-linked trialAbstract readReview
In one paragraph

Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07589374 (Correlation Between Carotid-Femoral Pulse Wave Velocity and Triglyceride-Glucose Index and Its Derived Metrics), which is not on this map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07589374 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Correlation Between Carotid-Femoral Pulse Wave Velocity and Triglyceride-Glucose Index and Its Derived Metrics

TypeobservationalSponsorHospital de BaseRan2026 to 2028Enrolled800ConditionsHypertension, Insulin Resistance Syndrome, Arterial Stiffness, Cardiovascular Risk
3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Clinical Use of the Triglycerides/Glucose (TyG) Index in the Early Assessment of Metabolic Alterations and Cardiovascular Remodeling in Essential Hypertensive Patients.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ke SongDepartment of Cardiovascular Medicine, Jincheng People's Hospital, Jincheng, Shanxi, China.
Yuwan XuThe First Clinical Hospital of Changzhi Medical College, Changzhi, Shanxi, China.
Shuairan WuThe First Clinical Hospital of Changzhi Medical College, Changzhi, Shanxi, China.
Xiaojie ZhangThe First Clinical Hospital of Changzhi Medical College, Changzhi, Shanxi, China.
Yi WangThe First Clinical Hospital of Changzhi Medical College, Changzhi, Shanxi, China.
Sancong PanDepartment of Cardiovascular Medicine, Jincheng People's Hospital, Jincheng, Shanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin resistance (IR) represents a pivotal metabolic risk factor, with metabolic abnormalities intricately linked to increased predisposition to cardiovascular, digestive, and immune system disorders. While the triglyceride glucose (TyG) index is widely recognized as a simple and specific surrogate marker for IR, the triglyceride glucose body mass index (TyG-BMI), incorporating obesity metrics, has emerged as a more robust predictor of IR. Growing evidence underscores the strong association between TyG-BMI index and multisystem diseases that span cardiovascular, metabolic, and neoplastic pathways. Monitoring TyG-BMI index enables proactive management of lifestyle modifications, dietary interventions, and physical health strategies, thereby reducing disease prevalence. This review synthesizes the pathophysiological mechanisms underlying TyG-BMI, alongside its clinical utility and cutting-edge research advancements in hypertension, coronary artery disease, stroke, diabetes, non-alcoholic fatty liver disease, hyperuricemia, and cancer. Particular emphasis is placed on the role of TyG-BMI index in influencing disease progression, highlighting its potential as a transformative biomarker for risk stratification and therapeutic targeting across diverse medical disciplines.

Indexed as

cardiovascular diseasediabetesinsulin resistanceresearch statustriglyceride glucose-body mass index

Identifiers

PMID40756600
PMCPMC12315701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.